查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1542897

全球皮膚和軟組織感染市場 - 2024-2031

Global Skin and Soft Tissue Infections Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

2023年，全球皮膚和軟組織感染市場達到112.8371億美元，預計到2031年將達到217.0855億美元，2024-2031年預測期間複合年成長率為8.8%。

皮膚和軟組織感染 (SSTI) 是皮膚、肌肉和結締組織（如韌帶和肌腱）的感染。 SSTI 最常見的原因是細菌，細菌可以透過各種開口進入人體，例如燒傷、微小割傷、擦傷和手術部位的傷口。

常見的單純性SSTI包括蜂窩性組織炎、丹毒、膿皰瘡、臁瘡、毛囊炎、癤、癰、膿瘍和創傷相關感染。複雜感染包括深部膿瘍、褥瘡、壞死性筋膜炎、福尼爾壞疽、人類或動物咬傷引起的感染。

市場動態：

驅動程式和限制

產品開發和批准不斷增加

用於治療皮膚和軟組織感染的藥物的不斷開發和批准預計將推動市場成長。隨著新藥的開發，將為感染者提供多種產品。這增加了對新治療產品的需求。

具有廣泛應用的產品批准不斷增加預計將增加對這些藥物的需求。例如，2024年4月，美國食品藥物管理局批准Zevtera（注射頭孢比普羅美多卡利鈉）用於治療成人金黃色葡萄球菌血流感染（菌血症）（SAB），包括右側感染性心內膜炎、成人急性細菌性皮膚及皮膚結構感染（ABSSSI）。

此外，2021年7月23日，艾伯維獲得美國食品藥物管理局（FDA）批准的DALVANCE（達巴萬星）用於治療出生後兒科患者的急性細菌性皮膚和皮膚結構感染（ABSSSI） 。 DALVANCE 是第一個以30 分鐘靜脈(IV) 輸注形式給藥的單劑量選擇，用於治療兒科患者由指定敏感革蘭氏陽性菌引起的ABSSSI，包括由耐甲氧西林金黃色葡萄球菌( MRSA) 引起的感染。因此，上述因素可能會推動市場成長。

對新的傳染性細菌菌株的抵抗力

耐萬古黴素腸球菌（VRE）和抗甲氧西林金黃色葡萄球菌（MRSA）等抗生素抗藥性細菌的出現，為SSTI的治療帶來了主要障礙。這降低了傳統抗生素的有效性，導致治療時間延長、醫療費用更高以及患者預後較差。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 產品開發和批准不斷增加
    • 限制
      • 對新的傳染性細菌菌株的抵抗力
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 報銷分析
  • 專利分析
  • SWOT分析
  • DMI 意見

第 6 章：按類型

  • 感染性潰瘍
  • 傷口感染
  • 膿腫
  • 蜂窩性組織炎
  • 外耳炎
  • 其他

第 7 章：按藥物類型

  • 抗生素
  • 抗真菌劑
  • 其他

第 8 章：依給藥途徑分類

  • 專題
  • 口服
  • 注射用

第 9 章：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 其他

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • GSK Plc
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Pfizer Inc.
  • Merck KGaA
  • Wellona Pharma
  • GL Pharma
  • Basilea Pharmaceutica AG
  • Invision Medi Sciences Pvt. Ltd.
  • Intelicure Lifesciences.
  • Steris Healthcare Pvt Ltd
  • SNU Biocare (*LIST NOT EXHAUSTIVE)

第 13 章：附錄

簡介目錄
Product Code: PH33

Market Overview

The Global Skin and Soft Tissue Infections Market reached US$ 11,283.71 million in 2023 and is expected to reach US$ 21,708.55 million by 2031, growing at a CAGR of 8.8% during the forecast period 2024-2031.

Skin and Soft Tissue Infections (SSTI) are infections of the skin, muscles, and connective tissue such as ligaments and tendons. The most frequent cause of SSTIs is bacteria, which can enter the body through a variety of openings such as burns, tiny cuts, scrapes, and wounds from surgical sites.

Common simple SSTIs include cellulitis, erysipelas, impetigo, ecthyma, folliculitis, furuncles, carbuncles, abscesses, and trauma-related infections. Complicated infections include deep abscesses, decubitus ulcers, necrotizing fasciitis, Fournier gangrene, and infections from human or animal bites.

Market Dynamics: Drivers & Restraints

Rising product development and approvals

The rising developments and approvals of the drugs for the treatment of Skin and Soft Tissue Infections is expected to drive the market growth. With the development of new drugs there will be a wide range of products available for the individuals with the infections. This rises the demand for the new products for the treatment.

The rising product approvals with broad spectrum applications is expected to increase the demand for the drugs. For instance, in April 2024, the U.S. Food and Drug Administration approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis, adults with acute bacterial skin and skin structure infections (ABSSSI).

Additionally, July 23, 2021, AbbVie received the U.S. Food and Drug Administration (FDA) approved DALVANCE (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. DALVANCE is the first single-dose option administered as a 30-minute intravenous (IV) infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Thus, the above factors could drive the market growth.

Resistance to the new strains of infectious bacteria

The emergence of antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA), presents a major obstacle to the treatment of SSTIs. This reduces the effectiveness of conventional antibiotics, leading to extended therapy times, higher medical expenses, and worse patient outcomes.

Segment Analysis

The global Skin and Soft Tissue Infections market is segmented based on type, drug type, route of Administration, distribution channel and region.

Antibiotics segment is expected to dominate the market share

Antibiotics segment holds a major position in the market share. For bacterial SSTIs, antibiotics are currently the primary form of treatment. They function well against a variety of bacterial pathogens, including Streptococcus pyogenes and Staphylococcus aureus, that can lead to skin infections. Antibiotics specifically target bacterial infections, that are a common cause of SSTIs.

The large number of prescriptions for and treatments for bacterial infections has created an significant position for antibiotics.

The market position of antibiotics is further built by ongoing research and development activities in antibiotic therapy, which lead to the creation of novel formulations, combinations, and enhanced efficacy against antibiotic-resistant bacteria. Thus, the above factors are expected to drive the segment growth.

Geographical Analysis

North America is expected to hold a significant position in the skin and soft tissue infections market share

North America is holding a dominant position in the market share owing to the increasing incidence of several Skin and Soft Tissue Infections in the region. The presence of a large number of pharmaceutical companies in the region is also expected to be a factor in the growth of the region's market.

The region has an advanced healthcare infrastructure with established hospitals and clinics. The hospitals and clinics have well-established diagnostic tools and the region also has well-established medical research and advancements in treatment options.

The increasing number of Skin and Soft Tissue Infections in the region increases demand for the new drugs that are developed in the region. For instance, according to the report by NIH in 2023, it is estimated that cellulitis is a very common skin infection that accounts for more than 14 million cases in the United States per year.

Additionally, according to the Agency for Healthcare Research and Quality, each year, more than 2.5 million people in the United States develop pressure ulcers. These skin lesions bring pain, associated risk for serious infection, and increased health care utilization. Pressure ulcers are associated with longer hospital stays and increased morbidity and mortality. Thus, the above factors are expected to hold the region in the dominant position.

Market Segmentation

By Type

Infected Ulcers

Wound Infections

Abscesses

Cellulitis

Otitis Externa

Others

By Drug Type

Antibiotics

Anti-fungal Agents

Others

By Route of Administration

Topical

Oral

Parenteral

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Competitive Landscape

The major global players in the market include GSK Plc, Pfizer Inc., Merck KGaA, Wellona Pharma, GL Pharma, Basilea Pharmaceutica AG, Invision Medi Sciences Pvt. Ltd., Intelicure Lifesciences., Steris Healthcare Pvt Ltd and SNU Biocare among others.

Why Purchase the Report?

To visualize the global skin and soft tissue infections market segmentation based on type, drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of skin and soft tissue infections market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as Excel consisting of key products of all the major players.

The global skin and soft tissue infections market report would provide approximately 53 tables, 47 figures, and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising product development and approvals
    • 4.1.2. Restraints
      • 4.1.2.1. Resistance to the new strains of infectious bacteria
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Infected Ulcers*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Wound Infections
  • 6.4. Abscesses
  • 6.5. Cellulitis
  • 6.6. Otitis Externa
  • 6.7. Others

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Antibiotics*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Anti-fungal Agents
  • 7.4. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Topical*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Oral
  • 8.4. Parenteral

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. UK
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. GSK Plc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Pfizer Inc.
  • 12.3. Merck KGaA
  • 12.4. Wellona Pharma
  • 12.5. GL Pharma
  • 12.6. Basilea Pharmaceutica AG
  • 12.7. Invision Medi Sciences Pvt. Ltd.
  • 12.8. Intelicure Lifesciences.
  • 12.9. Steris Healthcare Pvt Ltd
  • 12.10. SNU Biocare (*LIST NOT EXHAUSTIVE)

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us